Lexaria Bioscience (LEXX) Capital Expenditures Growth (1y) (2011 - 2026)
Lexaria Bioscience (LEXX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1,133.33% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -37.81% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 142.64% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.37% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -73.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 22,433.30% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 4,081,500.00% |
| Aug 31, 2025 | -100.00% |
| Nov 30, 2022 | -51.62% |
| Jul 31, 2014 | 123,856.00% |
| Jan 31, 2014 | -32.69% |
| Oct 31, 2013 | 0.71% |
| Jul 31, 2013 | -99.95% |
| Jan 31, 2013 | -17.83% |
| Oct 31, 2012 | -96.25% |
| Jan 31, 2012 | -81.31% |
| Oct 31, 2011 | 152.93% |